
Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial
MALVERN, PA — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) this week announced that the FDA approved enrolling pediatric patients in the ongoing OCU400 Phase 1/2 trial.
Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial Read More